Provexis plc (LSE:PXS) was among the most volatile UK stocks on 23 September 2026. The Reading-based company develops and sells Fruitflow, a tomato extract that it describes as scientifically proven to inhibit platelet aggregation, for use in dietary supplements and functional foods.
Proteome Sciences plc (LSE:PRM), the AIM-quoted protein biomarker and mass-spectrometry specialist, was named among the most volatile UK stocks on 23 September 2026. The listing followed a busy fortnight: on 15 September the company confirmed a further GCLP-grade chemoproteomics contract, and on 16 September …
ImmuPharma plc —LSE:IMMis in focus on September 24, 2026, after its shares fell17.04%in the trading data provided.
Provexis PLC (LSE:PXS) is attracting investor attention because it sits at the intersection ofhealthcare, functional foods and nutraceuticals, with Fruitflow representing the company's central commercial asset.
Those headlines follow first-half results in July that showedRevenueup 9% and coreEarnings Per Shareup 12%, with full-year guidance maintained. The company has also changed how its shares trade in the US, replacing its American Depositary Shares with a direct New York Stock Exchange listing …
Futura Medical has attracted renewed attention afterLSE:FUM gained 10.00% on 24 September 2026.
Cambridge Nutritional Sciences (LSE:CNSL) is back in focus after a13.33% share-price rise on 24 September 2026.
BSF Enterprise has been showing high-beta characteristics. The company owns three tissue-engineering subsidiaries: Lab-Grown Leather Ltd, which has promoted a "T-Rex Leather" material; 3D Bio-Tissues Ltd (3DBT), which makes cell-culture products and the ETSYL collagen-boosting peptide; and Kerato Ltd, which is developing a liquid …
hVIVO runs the world's largestQuarantineFacilityfor human challenge trials, in which healthy volunteers are deliberately exposed to a virus or bacterium so that aVaccineor antiviral can be tested quickly. The company is quoted on AIM, the London Stock Exchange's growth market, and has been showing …
Shield Therapeutics plc has been showing high-beta characteristics. The Gateshead-headquartered company is a commercial-stage pharmaceuticalBusinessfocused on iron deficiency, and its main product is ACCRUFeR (ferric maltol), an oral iron therapy sold as FeRACCRU in Europe.